Abstract
Background: The Breast and Ovarian Analysis of Disease Incidence Algorithm (BOADICEA) model predicts breast cancer risk using cancer family history, epidemiological, and genetic data. We evaluated its validity in a large prospective cohort. Methods: We assessed model calibration, discrimination and risk classification ability in 217 885 women (6838 incident breast cancers) aged 40-70 years of self-reported White ethnicity with no previous cancer from the UK Biobank. Age-specific risk classification was assessed using relative risk thresholds equivalent to the absolute lifetime risk categories of less than 17%, 17%-30%, and 30% or more, recommended by the National Institute for Health and Care Excellence guidelines. We predicted 10-year risks using BOADICEA v.6 considering cancer family history, questionnaire-based risk factors, a 313–single nucleotide polymorphisms polygenic score, and pathogenic variants. Mammographic density data were not available. Results: The polygenic risk score was the most discriminative risk factor (area under the curve [AUC] = 0.65). Discrimination was highest when considering all risk factors (AUC = 0.66). The model was well calibrated overall (expected-to-observed ratio = 0.99, 95% confidence interval [CI] = 0.97 to 1.02; calibration slope = 0.99, 95% CI = 0.99 to 1.00), and in deciles of predicted risks. Discrimination was similar in women aged younger and older than 50 years. There was some underprediction in women aged younger than 50 years (expected-to-observed ratio = 0.89, 95% CI = 0.84 to 0.94; calibration slope = 0.96, 95% CI = 0.94 to 0.97), which was explained by the higher breast cancer incidence in UK Biobank than the UK population incidence in this age group. The model classified 87.2%, 11.4%, and 1.4% of women in relative risk categories less than 1.6, 1.6-3.1, and at least 3.1, identifying 25.6% of incident breast cancer patients in category relative risk of at least 1.6. Conclusion: BOADICEA, implemented in CanRisk (www.canrisk.org), provides valid 10-year breast cancer risk, which can facilitate risk-stratified screening and personalized breast cancer risk management.
Funding Information
  • Medical Research Council (MR/N013433/1)
  • Cancer Research UK (PPRPGM-Nov20\100002)
  • National Institute for Health and Care Research
  • Cambridge Biomedical Research Centre (NIHR203312)
  • Gray Foundation
  • European Union’s Horizon 2020 (633784, 634935)
  • Genome Canada (#13529)
  • Canadian Institutes of Health Research (#155865)
  • Ministère de l’Économie et de l’Innovation du Québec through Genome Québec
  • Quebec Breast Cancer Foundation
  • CHU de Quebec
  • British Heart Foundation (RG/18/13/33946, RG/F/23/110103)
  • British Heart Foundation Chair (CH/12/2/29428)
  • Health Data Research UK
  • UK Medical Research Council
  • Engineering and Physical Sciences Research Council
  • Economic and Social Research Council
  • Department of Health and Social Care
  • Chief Scientist Office of the Scottish Government Health and Social Care Directorates
  • Health and Social Care Research and Development Division
  • Public Health Agency
  • British Heart Foundation
  • Wellcome Trust

This publication has 35 references indexed in Scilit: